Diagnosing and Treating Gout: A Review to Aid Primary Care Physicians

Abstract Generalist physicians, specifically general internists and primary care physicians, are often the first to see patients with gout and therefore play a critical role in the diagnosis and management of these patients. The aim of this review is to aid generalist physicians in diagnosing and treating gout. A case report example is presented to highlight some of the problems in diagnosing and treating gout. Practical practice points are also highlighted.

[1]  K. Saag,et al.  Gout medication treatment patterns and adherence to standards of care from a managed care perspective. , 2006, Mayo Clinic proceedings.

[2]  H. Schumacher,et al.  Febuxostat compared with allopurinol in patients with hyperuricemia and gout. , 2005, The New England journal of medicine.

[3]  F. Wolfe,et al.  The misdiagnosis of gout and hyperuricemia. , 1991, The Journal of rheumatology.

[4]  H. Yamanaka,et al.  Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment. , 1998, Advances in experimental medicine and biology.

[5]  Hyon K. Choi,et al.  Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. , 2005, Archives of internal medicine.

[6]  N. Schlesinger,et al.  Treatment of acute gout in hospitalized patients. , 2007, The Journal of rheumatology.

[7]  Naoyuki Kamatani,et al.  A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. , 2004, Arthritis and rheumatism.

[8]  B. Joffe,et al.  Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study , 2000, Annals of the rheumatic diseases.

[9]  F. Perez-Ruiz,et al.  Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout , 1998, Annals of the rheumatic diseases.

[10]  H. Schumacher,et al.  Local ice therapy during bouts of acute gouty arthritis. , 2002, The Journal of rheumatology.

[11]  R. Grahame,et al.  Clinical survey of 354 patients with gout. , 1970, Annals of the rheumatic diseases.

[12]  H. Schumacher,et al.  Crystal-associated arthropathies. , 1988, Clinics in geriatric medicine.

[13]  F. Perez-Ruiz,et al.  Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. , 2002, Arthritis and rheumatism.

[14]  N. Dalbeth,et al.  Allopurinol Dosing in Renal Impairment: Walking the Tightrope Between Adequate Urate Lowering and Adverse Events , 2007, Seminars in dialysis.

[15]  H. Schumacher,et al.  A survey of current evaluation and treatment of gout. , 2006, The Journal of rheumatology.

[16]  W. N. Kelley,et al.  Management of gout. , 1979, JAMA.

[17]  K. Hande,et al.  Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. , 1984, The American journal of medicine.

[18]  D. Mccarty,et al.  Preliminary criteria for the classification of the acute arthritis of primary gout. , 1977, Arthritis and rheumatism.

[19]  C. Weel,et al.  Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial , 2008, The Lancet.

[20]  N. Schlesinger.  Response to Application of Ice May Help Differentiate Between Gouty Arthritis and Other Inflammatory Arthritides , 2006, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[21]  H. Schumacher,et al.  Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? , 2001, The Journal of rheumatology.

[22]  P Netter,et al.  EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT) , 2006, Annals of the rheumatic diseases.

[23]  F. Breedveld,et al.  Withdrawal of longterm antihyperuricemic therapy in tophaceous gout. , 1993, The Journal of rheumatology.

[24]  N. Schlesinger.  Management of acute and chronic gouty arthritis: present state-of-the-art. , 2004, Drugs.

[25]  N. Schlesinger.  Overview of the Management of Acute Gout and the Role of Adrenocorticotropic Hormone , 2012, Drugs.

[26]  I. Sketris,et al.  Gout in the Elderly — A Population Health Study , 2009, The Journal of Rheumatology.

[27]  N. Dalbeth,et al.  Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. , 2006, The Journal of rheumatology.

[28]  L. Naldi,et al.  Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. , 2008, Journal of the American Academy of Dermatology.

[29]  P Netter,et al.  EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT) , 2006, Annals of the rheumatic diseases.

[30]  Bullock Pw,et al.  Intermittent control of hyperuricemia in the treatment of gout. , 1989 .

[31]  N. Schlesinger,et al.  Serum Urate During Acute Gout , 2009, The Journal of Rheumatology.

[32]  J. Tenenbaum,et al.  Coexistent septic and crystal arthritis. Report of four cases and literature review. , 1986, The Journal of rheumatology.